Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?
- PMID: 31553842
- DOI: 10.1056/NEJMe1910742
Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?
Comment on
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical